心脏移植后严重原发性移植物功能障碍的临床特征和预后:时间重要吗?

IF 1.9 4区 医学 Q2 SURGERY
Yosef Manla, David H. Chang, Peter Deckerman, Michelle Kittleson, Fardad Esmailian, Avani Kanungo, Evan P. Kransdorf, Jillian Max, Andriana Nikolova, Lawrence S. Czer, Lily Stern, Jon A. Kobashigawa
{"title":"心脏移植后严重原发性移植物功能障碍的临床特征和预后:时间重要吗?","authors":"Yosef Manla,&nbsp;David H. Chang,&nbsp;Peter Deckerman,&nbsp;Michelle Kittleson,&nbsp;Fardad Esmailian,&nbsp;Avani Kanungo,&nbsp;Evan P. Kransdorf,&nbsp;Jillian Max,&nbsp;Andriana Nikolova,&nbsp;Lawrence S. Czer,&nbsp;Lily Stern,&nbsp;Jon A. Kobashigawa","doi":"10.1111/ctr.70305","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Severe left ventricular/biventricular primary graft dysfunction (PGD-LV) continues to be a major contributor to 30-day mortality post-heart transplantation (HTx). In patients with severe PGD-LV, two distinctive presentation phenotypes are encountered: an “immediate PGD” (IP), where patients fail to wean from cardiopulmonary bypass (CPB), or a “delayed PGD” (DP) following successful weaning from CPB and/or transfer from the operating room. Data on these phenotypes' incidence, associated characteristics, and outcomes remain limited. Therefore, we assessed patient characteristics and 1-year post-HTx outcomes associated with IP versus DP.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Between 2010 and 2022, we included 47 HTx patients with severe PGD-LV. Patients were divided into those with IP (<i>n</i> = 16) and those with DP (<i>n</i> = 31). Endpoints included 30-day and 1-year survival, as well as 1-year freedom from any-treated rejection (ATR), acute cellular rejection (ACR), antibody-mediated rejection (AMR), biopsy-negative rejection (BNR), cardiac allograft vasculopathy (CAV), non-fatal major adverse cardiac events (NF-MACE), and freedom from left ventricular dysfunction (LVD).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Compared to patients with DP, those with IP had a higher prevalence of pre-HTx sensitization (56.3% vs. 19.4%, <i>p</i> = 0.01) and tended to receive hearts from older donors (47.5 vs. 34 years, <i>p</i> = 0.055). They had decreased survival rates at 30 days (50% vs. 77.4%, <i>p</i> = 0.043) and 1-year post-HTx (31.2% vs. 61.1%, <i>p</i> = 0.029). No significant differences were recorded in 1-year freedom from CAV, ATR, ACR, AMR, BNR, NF-MACE, or LVD.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Immediate presentation of severe PGD-LV appeared to be associated with pre-HTx sensitization and use of older donor hearts and conferred a worse post-HTx survival.</p>\n </section>\n </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"39 9","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical Characteristics and Outcomes Associated With Immediate Versus Delayed Presentation of Severe Primary Graft Dysfunction After Heart Transplantation: Does Timing Matter?\",\"authors\":\"Yosef Manla,&nbsp;David H. Chang,&nbsp;Peter Deckerman,&nbsp;Michelle Kittleson,&nbsp;Fardad Esmailian,&nbsp;Avani Kanungo,&nbsp;Evan P. Kransdorf,&nbsp;Jillian Max,&nbsp;Andriana Nikolova,&nbsp;Lawrence S. Czer,&nbsp;Lily Stern,&nbsp;Jon A. Kobashigawa\",\"doi\":\"10.1111/ctr.70305\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Severe left ventricular/biventricular primary graft dysfunction (PGD-LV) continues to be a major contributor to 30-day mortality post-heart transplantation (HTx). In patients with severe PGD-LV, two distinctive presentation phenotypes are encountered: an “immediate PGD” (IP), where patients fail to wean from cardiopulmonary bypass (CPB), or a “delayed PGD” (DP) following successful weaning from CPB and/or transfer from the operating room. Data on these phenotypes' incidence, associated characteristics, and outcomes remain limited. Therefore, we assessed patient characteristics and 1-year post-HTx outcomes associated with IP versus DP.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Between 2010 and 2022, we included 47 HTx patients with severe PGD-LV. Patients were divided into those with IP (<i>n</i> = 16) and those with DP (<i>n</i> = 31). Endpoints included 30-day and 1-year survival, as well as 1-year freedom from any-treated rejection (ATR), acute cellular rejection (ACR), antibody-mediated rejection (AMR), biopsy-negative rejection (BNR), cardiac allograft vasculopathy (CAV), non-fatal major adverse cardiac events (NF-MACE), and freedom from left ventricular dysfunction (LVD).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Compared to patients with DP, those with IP had a higher prevalence of pre-HTx sensitization (56.3% vs. 19.4%, <i>p</i> = 0.01) and tended to receive hearts from older donors (47.5 vs. 34 years, <i>p</i> = 0.055). They had decreased survival rates at 30 days (50% vs. 77.4%, <i>p</i> = 0.043) and 1-year post-HTx (31.2% vs. 61.1%, <i>p</i> = 0.029). No significant differences were recorded in 1-year freedom from CAV, ATR, ACR, AMR, BNR, NF-MACE, or LVD.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Immediate presentation of severe PGD-LV appeared to be associated with pre-HTx sensitization and use of older donor hearts and conferred a worse post-HTx survival.</p>\\n </section>\\n </div>\",\"PeriodicalId\":10467,\"journal\":{\"name\":\"Clinical Transplantation\",\"volume\":\"39 9\",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Transplantation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/ctr.70305\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Transplantation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ctr.70305","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

摘要

背景:严重的左心室/双心室原发性移植物功能障碍(PGD-LV)仍然是心脏移植(HTx)后30天死亡率的主要原因。在严重PGD- lv患者中,会遇到两种不同的表现表型:“立即PGD”(IP),即患者未能脱离体外循环(CPB),或“延迟PGD”(DP),即成功脱离CPB和/或从手术室转移。关于这些表型的发生率、相关特征和结果的数据仍然有限。因此,我们评估了患者特征和htx后1年与IP和DP相关的结果。方法2010年至2022年间,我们纳入了47例HTx合并重度PGD-LV患者。患者分为IP组(n = 16)和DP组(n = 31)。终点包括30天和1年的生存期,以及1年无任何治疗的排斥反应(ATR)、急性细胞排斥反应(ACR)、抗体介导的排斥反应(AMR)、活检阴性排斥反应(BNR)、同种异体心脏移植血管病变(CAV)、非致命性主要心脏不良事件(NF-MACE)和无左心室功能障碍(LVD)。结果与DP患者相比,IP患者有更高的htx前致敏率(56.3% vs. 19.4%, p = 0.01),并倾向于接受老年供者的心脏(47.5 vs. 34岁,p = 0.055)。术后30天生存率(50% vs. 77.4%, p = 0.043)和术后1年生存率(31.2% vs. 61.1%, p = 0.029)均有下降。CAV、ATR、ACR、AMR、BNR、NF-MACE或LVD的1年无显著性差异。结论:严重PGD-LV的立即出现似乎与htx前致敏和使用较老的供体心脏有关,并赋予htx后更差的生存。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Clinical Characteristics and Outcomes Associated With Immediate Versus Delayed Presentation of Severe Primary Graft Dysfunction After Heart Transplantation: Does Timing Matter?

Background

Severe left ventricular/biventricular primary graft dysfunction (PGD-LV) continues to be a major contributor to 30-day mortality post-heart transplantation (HTx). In patients with severe PGD-LV, two distinctive presentation phenotypes are encountered: an “immediate PGD” (IP), where patients fail to wean from cardiopulmonary bypass (CPB), or a “delayed PGD” (DP) following successful weaning from CPB and/or transfer from the operating room. Data on these phenotypes' incidence, associated characteristics, and outcomes remain limited. Therefore, we assessed patient characteristics and 1-year post-HTx outcomes associated with IP versus DP.

Methods

Between 2010 and 2022, we included 47 HTx patients with severe PGD-LV. Patients were divided into those with IP (n = 16) and those with DP (n = 31). Endpoints included 30-day and 1-year survival, as well as 1-year freedom from any-treated rejection (ATR), acute cellular rejection (ACR), antibody-mediated rejection (AMR), biopsy-negative rejection (BNR), cardiac allograft vasculopathy (CAV), non-fatal major adverse cardiac events (NF-MACE), and freedom from left ventricular dysfunction (LVD).

Results

Compared to patients with DP, those with IP had a higher prevalence of pre-HTx sensitization (56.3% vs. 19.4%, p = 0.01) and tended to receive hearts from older donors (47.5 vs. 34 years, p = 0.055). They had decreased survival rates at 30 days (50% vs. 77.4%, p = 0.043) and 1-year post-HTx (31.2% vs. 61.1%, p = 0.029). No significant differences were recorded in 1-year freedom from CAV, ATR, ACR, AMR, BNR, NF-MACE, or LVD.

Conclusion

Immediate presentation of severe PGD-LV appeared to be associated with pre-HTx sensitization and use of older donor hearts and conferred a worse post-HTx survival.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical Transplantation
Clinical Transplantation 医学-外科
CiteScore
3.70
自引率
4.80%
发文量
286
审稿时长
2 months
期刊介绍: Clinical Transplantation: The Journal of Clinical and Translational Research aims to serve as a channel of rapid communication for all those involved in the care of patients who require, or have had, organ or tissue transplants, including: kidney, intestine, liver, pancreas, islets, heart, heart valves, lung, bone marrow, cornea, skin, bone, and cartilage, viable or stored. Published monthly, Clinical Transplantation’s scope is focused on the complete spectrum of present transplant therapies, as well as also those that are experimental or may become possible in future. Topics include: Immunology and immunosuppression; Patient preparation; Social, ethical, and psychological issues; Complications, short- and long-term results; Artificial organs; Donation and preservation of organ and tissue; Translational studies; Advances in tissue typing; Updates on transplant pathology;. Clinical and translational studies are particularly welcome, as well as focused reviews. Full-length papers and short communications are invited. Clinical reviews are encouraged, as well as seminal papers in basic science which might lead to immediate clinical application. Prominence is regularly given to the results of cooperative surveys conducted by the organ and tissue transplant registries. Clinical Transplantation: The Journal of Clinical and Translational Research is essential reading for clinicians and researchers in the diverse field of transplantation: surgeons; clinical immunologists; cryobiologists; hematologists; gastroenterologists; hepatologists; pulmonologists; nephrologists; cardiologists; and endocrinologists. It will also be of interest to sociologists, psychologists, research workers, and to all health professionals whose combined efforts will improve the prognosis of transplant recipients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信